Positron emission tomography for benign and malignant disease
- PMID: 21184913
- PMCID: PMC3021752
- DOI: 10.1016/j.suc.2010.10.012
Positron emission tomography for benign and malignant disease
Abstract
Functional imaging using radiolabeled probes that specifically bind and accumulate in target tissues has improved the sensitivity and specificity of conventional imaging. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) has shown improved diagnostic accuracy in differentiating benign from malignant lesions in the setting of solitary pulmonary nodules. FDG-PET has become useful in preoperative staging of patients with lung cancer, and is being tested with many other malignancies for its ability to change patient management. This article provides an overview of the current status of FDG-PET and presents the challenges of moving toward routine use.
Copyright © 2011 Elsevier Inc. All rights reserved.
Figures
References
-
- Antonini A, DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med. 2004 Mar;5(2):201–206. - PubMed
-
- Ceballos-Baumann AO. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. J Neurol. 2003 Feb;250 Suppl 1:I15–I23. - PubMed
-
- Fukuyama H. Functional brain imaging in Parkinson's disease-overview. J Neurol. 2004 Oct;251 Suppl 7:vII1–vII3. - PubMed
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar–Apr;58(2):71–96. - PubMed
-
- Higgins GA, Shields TW, Keehn RJ. The solitary pulmonary nodule. Ten-year follow-up of veterans administration-armed forces cooperative study. Arch Surg. 1975 May;110(5):570–575. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
